INMED PHARMACEUTICALS INC. Deferred Costs
INMED PHARMACEUTICALS INC. (INM) had Deferred Costs of $63.87 thousand as of 2022-12-31, per its 10-Q filed 2023-02-17.
Discontinued › Balance Sheet › Assets
us-gaap:DeferredCostsCurrentAndNoncurrent · last filed 2023-02-17
- 2022-12-31: Deferred Costs $63.87K.
- 2022-09-30: Deferred Costs $106.19K.
- 2022-06-30: Deferred Costs $26.59K.
- 2022-03-31: Deferred Costs $138.93K.
| Period end | Deferred Costs | Deferred Costs as first filed |
|---|---|---|
| 2022-12-31 | $63.87K 10-Q · filed 2023-02-17 | |
| 2022-09-30 | $106.19K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $26.59K 10-K · filed 2022-09-23 | |
| 2022-03-31 | $138.93K 10-Q · filed 2022-05-13 | |
| 2021-09-30 | $179.12K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $164.81K 10-K · filed 2022-09-23 | $112.08K 10-K · filed 2021-09-24 |
| 2020-12-31 | $328.85K 10-Q · filed 2022-02-14 | |
| 2020-09-30 | $171.72K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |